Most “Promising” Biomedical Results Fail! Not Because They Were Wrong, But Because They Were Right in the Wrong Context

Article

Most teams explain late-stage failure with familiar labels:

• “Biology is hard.”
• “The animal model wasn’t predictive.”
• “The trial was underpowered.”
• “Regulators are strict.”
• “The execution team wasn’t strong.”

Sometimes those are true. But the pattern underneath many failures is different — and more actionable:

A result can be scientifically correct… and still fail because the context moved.

This failure mode has a name:
Context Shift

Context Shift happens when a signal that was real in one environment is carried into a new environment where the surrounding assumptions are no longer true.

The lab is a context. The Phase I cohort is a context. A single academic medical center is a context. A curated dataset is a context.

And the real world — heterogeneous patients, variable sites, imperfect adherence, noisy measurement, changing variants, changing incentives — is an entirely different context.

So the problem is not simply “Did it work?” The problem is:

Here’s the reframing that changes decisions

In translational work, the most expensive errors are not caused by “false results.”

They’re caused by local truths being treated as global truths.

A program can be built on strong internal validity — and still collapse when:

• the patient mix shifts,
• measurement standards differ across sites,
• protocols drift in real operations,
• biology interacts with population genetics,
• the workflow changes what “data” even means.

In other words:

Uncertainty is not the enemy. Unmapped context is.

If you want a sharper term for the silent accumulation of untested assumptions that builds up between “proof” and “practice,” it’s this:

The mental model most teams are missing

This is the distinction that, once you see it, you can’t unsee:

Most teams unconsciously assume:

“If it works biologically, it will work operationally.”
That assumption quietly kills programs.

Because the two questions are different — and require different tests.

The line that should change how “scale” is treated

Here is the sentence I wish every R&D and product team pinned to their wall:

Scale-up is not a milestone. It’s a hypothesis test.

Industry culture treats scale as celebration. Reality treats scale as stress.

If you scale without testing transferability and scalability, you’re not “advancing.” You’re betting. And when the bet fails, it usually fails late — after the expensive phase begins.

Real-world examples (one sentence each)

You don’t need ten examples. One per domain is enough to see the pattern.

• Drug development: Phase II is where many candidates die — not because the early signal was fake, but because the human context exposed what early contexts couldn’t.
• AI in healthcare: A widely deployed sepsis prediction model can look acceptable in one environment and underperform in external settings — creating alert burden without reliable clinical value.
• Measurement & equity: Even “standard” devices like pulse oximeters have shown performance gaps across populations — a reminder that representativeness and measurement assumptions are not optional.

Different domains. Same mechanism: context moved.

So what do you do before a big decision?

You run a deliberate check before you spend the next year (or the next €10M) learning something you could have learned in weeks.

Before major scale decisions, I run what I call a Stage-0 Transferability & Scalability Check.

Not a heavy “modeling project.” Not a long engagement. A decision gate — designed to surface and pay down context debt early.

Stage-0 forces five uncomfortable but high-leverage questions

1. Where will context shift hit first? Population, site, protocol, measurement, workflow — what changes when we leave the original environment?
2. Which assumptions must hold for the signal to remain real? Not “everything,” just the few assumptions that decide success vs. failure.
3. What is missing from the evidence for external validity? Which subgroup, site condition, measurement condition, or operational behavior is untested?
4. What is the minimum next test that collapses uncertainty? Not “more experiments.” The right validation that changes the decision.
5. What would a “fast fail” look like now—on paper—before it becomes an expensive fail later? Because in real R&D, fast fail is often the second-best outcome.

This is how failure becomes modelable — not motivational, not vague, not blamed on “complexity.”

The decision-grade takeaway

Most failures are not because the science was weak. They’re because the science was local — and nobody tested whether it could travel or survive pressure.

So the next time a program looks “promising,” ask two separate questions:

• Did we test transferability?
• Did we test scalability?

A practical next step (that stays in the “thinker tool” frame)

If this lens resonates, try it once on your current project:

That 10-minute exercise often reveals where the real risk is hiding.

And if you want a structured version of that exercise, I’ve formalized it as Stage-0 at Method2Model: a short, non-sensitive intake that outputs a concise feasibility note—where context debt is accumulating, what would break at scale, and what the minimum next test should be.